2024
Chapter 21 Gamma Knife for psychiatric indications
Lopes A, de Arruda I, Batistuzzo M, Gorgulho A, de Salles A, Miguel E. Chapter 21 Gamma Knife for psychiatric indications. 2024, 495-517. DOI: 10.1016/b978-0-443-18496-3.00021-5.Peer-Reviewed Original ResearchAnorexia nervosaObsessive-compulsive disorder patientsTreatment of psychiatric disordersAnterior limb of internal capsuleObsessive-compulsive disorderVentral anterior limbGamma KnifeGK radiosurgeryMajor depressionDisorder patientsPsychiatric disordersPsychiatric indicationsNervosaDepressionInternal capsuleSurgical modalitiesAdverse eventsDisordersAnorexiaRadiosurgeryWeight gainManiaPsychiatryBrain cystsComplications
2022
Shape analysis of subcortical structures in obsessive‐compulsive disorder and the relationship with comorbid anxiety, depression, and medication use: A meta‐analysis by the OCD Brain Imaging Consortium
Fouche J, Groenewold N, Sevenoaks T, Heany S, Lochner C, Alonso P, Batistuzzo M, Cardoner N, Ching C, de Wit S, Gutman B, Hoexter M, Jahanshad N, Kim M, Kwon J, Mataix‐Cols D, Menchon J, Miguel E, Nakamae T, Phillips M, Pujol J, Sakai Y, Yun J, Soriano‐Mas C, Thompson P, Yamada K, Veltman D, van den Heuvel O, Stein D. Shape analysis of subcortical structures in obsessive‐compulsive disorder and the relationship with comorbid anxiety, depression, and medication use: A meta‐analysis by the OCD Brain Imaging Consortium. Brain And Behavior 2022, 12: e2755. PMID: 36106505, PMCID: PMC9575597, DOI: 10.1002/brb3.2755.Peer-Reviewed Original ResearchConceptsCaudate nucleusHealthy controlsOCD patientsComorbid depressionMedication statusComorbid anxietySubcortical shapeSignificant differencesDeep gray matter structuresRight caudate nucleusCo-morbid anxietyLeft caudate nucleusObsessive-compulsive disorder patientsSubcortical brain morphologyGray matter structuresDisease durationMedication useObsessive-compulsive disorderSubgroup analysisBrain MRINucleus accumbensDisorder patientsPatientsBrain volumePutamen
2021
The impact of generalized anxiety disorder in obsessive-compulsive disorder patients.
Sharma P, Rosário M, Ferrão Y, Albertella L, Miguel E, Fontenelle L. The impact of generalized anxiety disorder in obsessive-compulsive disorder patients. Psychiatry Research 2021, 300: 113898. PMID: 33812219, DOI: 10.1016/j.psychres.2021.113898.Peer-Reviewed Original ResearchConceptsGeneralized anxiety disorderObsessive-compulsive disorderComorbid generalized anxiety disorderAnxiety disordersOnset of OCDType II bipolar disorderDiagnosis of GADTreatment of OCDObsessive-compulsive disorder patientsSevere anxiety symptomsMann-Whitney U testChi-square testPrevalent comorbiditiesClinical profileClinical severityMood disordersDisorder patientsComorbid anxietyPanic disorderBipolar disorderAvoidant behaviorComorbiditiesGreater suicidalityLogistic regressionU test
2019
No evidence of attentional bias toward angry faces in patients with obsessive-compulsive disorder
Skinazi M, de Mathis M, Cohab T, de Marco e Souza M, Shavitt R, Miguel E, Hoexter M, Batistuzzo M. No evidence of attentional bias toward angry faces in patients with obsessive-compulsive disorder. Brazilian Journal Of Psychiatry 2019, 41: 257-260. PMID: 30540026, PMCID: PMC6794136, DOI: 10.1590/1516-4446-2018-0130.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderAttentional biasAngry facesAnxiety disorder patientsOCD patientsDifferent brain activation patternsFunctional neuroimaging protocolsSpecific OCD symptom dimensionsBrain activation patternsSymptom severityOCD symptom dimensionsDisorder patientsAB taskAB paradigmTransdiagnostic approachAB scoresIntelligence testingAnxiety disordersSymptom dimensionsActivation patternsNeuroimaging protocolPsychiatric comorbidityOne-sample t-testFaceDisorders
2013
The impact of comorbid body dysmorphic disorder on the response to sequential pharmacological trials for obsessive-compulsive disorder
Diniz J, Costa D, Cassab R, Pereira C, Miguel E, Shavitt R. The impact of comorbid body dysmorphic disorder on the response to sequential pharmacological trials for obsessive-compulsive disorder. Journal Of Psychopharmacology 2013, 28: 603-611. PMID: 24288238, DOI: 10.1177/0269881113512042.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntidepressive Agents, Second-GenerationAntidepressive Agents, TricyclicAntipsychotic AgentsBody Dysmorphic DisordersBrazilClomipramineComorbidityDrug Therapy, CombinationFemaleFluoxetineHumansMaleObsessive-Compulsive DisorderProspective StudiesQuetiapine FumarateRisk FactorsTreatment OutcomeConceptsBody dysmorphic disorderComorbid body dysmorphic disorderPharmacological trialsDysmorphic disorderAdult obsessive-compulsive disorder (OCD) patientsSequential treatment strategyObsessive-compulsive disorder patientsSequential treatmentFluoxetine monotherapyClinical characteristicsObsessive-compulsive disorderInitial severityTreatment strategiesDisorder patientsTreatment groupsPatientsWorse responseBDD patientsEffects of sexGEE modelTrialsDisordersSequential trialsWeeksType of augmentationCan early improvement be an indicator of treatment response in obsessive-compulsive disorder? Implications for early-treatment decision-making
da Conceição Costa D, Shavitt R, Cesar R, Joaquim M, Borcato S, Valério C, Miguel E, Diniz J. Can early improvement be an indicator of treatment response in obsessive-compulsive disorder? Implications for early-treatment decision-making. Journal Of Psychiatric Research 2013, 47: 1700-1707. PMID: 23948637, DOI: 10.1016/j.jpsychires.2013.07.006.Peer-Reviewed Original ResearchConceptsBaseline Y-BOCS scoresSerotonin reuptake inhibitorsEarly improvementTreatment responseY-BOCS scoresBaseline Yale-Brown ObsessiveLogistic regressionAdequate pharmacological treatmentPotential predictive factorsWeeks of treatmentGreater reductionObsessive-compulsive disorder patientsStepwise logistic regressionWarrants further investigationYale-Brown ObsessiveClinical featuresReuptake inhibitorsObsessive-compulsive disorderPharmacological treatmentPredictive factorsMajor depressionDisorder patientsOCD treatment responseCompulsive ScaleWeeks
2011
A Double-Blind, Randomized, Controlled Trial of Fluoxetine Plus Quetiapine or Clomipramine Versus Fluoxetine Plus Placebo for Obsessive-Compulsive Disorder
Diniz J, Shavitt R, Fossaluza V, Koran L, de Bragança Pereira C, Miguel E. A Double-Blind, Randomized, Controlled Trial of Fluoxetine Plus Quetiapine or Clomipramine Versus Fluoxetine Plus Placebo for Obsessive-Compulsive Disorder. Journal Of Clinical Psychopharmacology 2011, 31: 763-768. PMID: 22020357, DOI: 10.1097/jcp.0b013e3182367aee.Peer-Reviewed Original ResearchConceptsY-BOCS scoresFluoxetine groupTreatment regimenSelective serotonin reuptake inhibitorsPlacebo-controlled trialSevere adverse eventsSerotonin reuptake inhibitorsMain outcome measuresObsessive-compulsive disorder patientsCompulsive Scale scoresYale-Brown ObsessiveFluoxetine monotherapyAdverse eventsReuptake inhibitorsObsessive-compulsive disorderPrimary diagnosisOutcome measuresDisorder patientsScale scoreFluoxetineMental disordersQuetiapinePatientsStatistical ManualClomipramineRisk factors for early treatment discontinuation in patients with obsessive-compulsive disorder
Diniz J, Malavazzi D, Fossaluza V, Belotto-Silva C, Borcato S, Pimentel I, Miguel E, Shavitt R. Risk factors for early treatment discontinuation in patients with obsessive-compulsive disorder. Clinics 2011, 66: 387-393. PMID: 21552660, PMCID: PMC3071996, DOI: 10.1590/s1807-59322011000300004.Peer-Reviewed Original ResearchConceptsEarly treatment discontinuationSelective serotonin reuptake inhibitorsTreatment discontinuationObsessive-compulsive disorder patientsObsessive-compulsive disorderDisorder patientsFirst-line treatmentGroup of patientsSerotonin reuptake inhibitorsStructured Clinical InterviewLogistic regression analysisLogistic regression modelsGeneralized anxiety disorderCognitive behavioral therapyMann-Whitney testClinical characteristicsCompliant patientsDiscontinuation ratesReuptake inhibitorsPsychiatric comorbidityClinical correlatesTreatment modalitiesRisk factorsSomatization disorderDiscontinuation
2010
Comorbid major depression in obsessive-compulsive disorder patients
Quarantini L, Torres A, Sampaio A, Fossaluza V, de Mathis M, do Rosário M, Fontenelle L, Ferrão Y, Cordioli A, Petribu K, Hounie A, Miguel E, Shavitt R, Koenen K. Comorbid major depression in obsessive-compulsive disorder patients. Comprehensive Psychiatry 2010, 52: 386-393. PMID: 21087765, DOI: 10.1016/j.comppsych.2010.09.006.Peer-Reviewed Original ResearchConceptsMajor depressive disorderObsessive-compulsive disorderOCD patientsCurrent major depressive disorderComorbid major depressive disorderLifetime major depressive disorderComprehensive psychiatric evaluationComorbid major depressionSevere general psychopathologyHigher severity scoresObsessive-compulsive disorder patientsSymptom dimensionsOCD symptom dimensionsClinical characteristicsFrequent complicationSeverity scoreDepressive disorderMajor depressionPrevalence ratesPsychiatric evaluationDisorder patientsPatientsGeneral psychopathologyDisordersOCD symptoms
2009
The drug-naïve OCD patients imaging genetics, cognitive and treatment response study: methods and sample description
Hoexter M, Shavitt R, D'Alcante C, Cecconi J, Diniz J, Belotto-Silva C, Hounie A, Borcato S, Moraes I, Joaquim M, Cappi C, Sampaio A, de Mathis M, Batistuzzo M, Lopes A, Rosa A, Muniz R, Marques A, Santos L, Taub A, de Souza Duran F, Dougherty D, Busatto G, Bressan R, Miguel E. The drug-naïve OCD patients imaging genetics, cognitive and treatment response study: methods and sample description. Brazilian Journal Of Psychiatry 2009, 31: 349-353. PMID: 20098825, DOI: 10.1590/s1516-44462009000400011.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorder patientsObsessive-compulsive disorderNeuropsychological evaluationClinical trialsGroup cognitive behavioral therapyDisorder patientsTRODAT-1 single photon emissionIntegrative neurobiological modelCognitive behavioral therapySelective serotonin reuptake inhibitorsAdult obsessive-compulsive disorder (OCD) patientsMagnetic resonance imagesDrug-naïve OCD patientsDrug-naïve patientsSerotonin reuptake inhibitorsSame research procedureNeurobiological modelsSingle photon emissionResonance imagesTreatment response studiesOCD patientsReuptake inhibitorsHealthy controlsBlood samplesPatientsTreatment of Resistant Obsessive-Compulsive Disorder With Ventral CapsularVentral Striatal Gamma Capsulotomy: A Pilot Prospective Study
Lopes A, Greenberg B, Norén G, Canteras M, Busatto G, de Mathis M, Taub A, D'Alcante C, Hoexter M, Gouvea F, Cecconi J, Gentil A, Ferrão Y, Fuentes D, de Castro C, Leite C, Salvajoli J, Duran F, Rasmussen S, Miguel E. Treatment of Resistant Obsessive-Compulsive Disorder With Ventral CapsularVentral Striatal Gamma Capsulotomy: A Pilot Prospective Study. Journal Of Neuropsychiatry 2009, 21: 381-392. PMID: 19996246, DOI: 10.1176/jnp.2009.21.4.381.Peer-Reviewed Original ResearchConceptsResistant obsessive-compulsive disorderRefractory OCD patientsAdverse effectsPilot prospective studyObsessive-compulsive disorder patientsAdverse eventsProspective studyObsessive-compulsive disorderStereotactic radiosurgeryDepressive symptomsDisorder patientsSide effectsConventional treatmentCapsulotomyTherapeutic promisePatientsOCD patientsTreatmentSurgeryRadiosurgerySymptomsMonths
2007
Resistência e refratariedade no transtorno obsessivo-compulsivo
Ferrão Y, Diniz J, Lopes A, Shavitt R, Greenberg B, Miguel E. Resistência e refratariedade no transtorno obsessivo-compulsivo. Brazilian Journal Of Psychiatry 2007, 29: s66-s76. PMID: 18172943, DOI: 10.1590/s1516-44462006005000059.Peer-Reviewed Original ResearchMeSH KeywordsAntidepressive AgentsAntipsychotic AgentsBehavior TherapyClinical Trials as TopicCombined Modality TherapyDrug ResistanceDrug ToleranceFamily RelationsHumansMeta-Analysis as TopicObsessive-Compulsive DisorderPsychiatric Status Rating ScalesPsychotherapySelective Serotonin Reuptake InhibitorsConceptsObsessive-compulsive disorder patientsObsessive-compulsive disorderTherapeutic alternativeDisorder patientsConventional treatmentEffective therapeutic alternativeCompulsive disorder patientsAvailable treatmentsTreatment responseClinical challengeTreatment resistanceSymptom remissionAdequate treatmentPatient sufferingPatientsCurrent conceptsRemissionMore studiesTreatmentDisordersSignificant numberLiterature reviewUnanswered questionsExtrinsic factors
2004
Impact of age at onset and duration of illness on the expression of comorbidities in obsessive-compulsive disorder.
Diniz J, Rosario-Campos M, Shavitt R, Curi M, Hounie A, Brotto S, Miguel E. Impact of age at onset and duration of illness on the expression of comorbidities in obsessive-compulsive disorder. The Journal Of Clinical Psychiatry 2004, 65: 22-7. PMID: 14744164, DOI: 10.4088/jcp.v65n0104.Peer-Reviewed Original ResearchConceptsDuration of illnessDepressive disorderTic disordersObsessive-compulsive symptomsExpression of comorbiditiesCommon etiologic pathwayLonger illness durationStructured Clinical InterviewDSM-IV criteriaObsessive-compulsive disorder patientsImpact of ageBody dysmorphic disorderConsecutive outpatientsSecondary complicationsObsessive-compulsive disorderPsychiatric comorbidityIllness durationEtiologic pathwaysDisorder patientsClinical InterviewComorbid diagnosesComorbiditiesIllnessAnxiety disordersDysmorphic disorder
2001
OCD and transvestism:is there a relationship?
Abdo C, Hounie A, De Tubino Scanavino M, Miguel E. OCD and transvestism:is there a relationship? Acta Psychiatrica Scandinavica 2001, 103: 471-473. PMID: 11401663, DOI: 10.1034/j.1600-0447.2001.00294.x.Peer-Reviewed Original Research